Startseite - PerioTrap Pharmaceuticals

MainBanner

PerioTrap is a clinical stage Biotech company that aims to eradicate the root cause of periodontitis

Background

Periodontitis is an inflammation of the gums mainly caused by a microbiotic shift towards pathogenic bacteria.

Periodontitis is an inflammation of the gums mainly caused by a microbiotic shift towards pathogenic bacteria. This shift leads to receding gums, bone and tooth loss and even chronic diseases.

Approach

PerioTrap has created a microbiome modulator designed to selectively target and inhibit pathogenic bacteria. This allows beneficial commensal bacteria to thrive and occupy ecological niches, thereby reducing the risk of future infections. By supporting the growth of healthy bacteria, the modulator helps preserve the natural barrier function of the microbiome, contributing to overall oral health.

Team

PerioTrap possesses many years of experience in drug development. The company’s team combines competences in the field of medicinal chemistry, compound characterization, microbiology, clinical and product development.

The collective track record includes the successful development of several drug development projects in the area of small molecules. This includes the development of DP4 inhibitors as antidiabetics and the development of a novel pharmacological approach for the treatment of Alzheimer's disease (currently in phase IIb).

Team members

Dr. Mirko Buchholz

CSO

Mirko is the CSO of PerioTrap Pharmaceuticals with 20 years of experience in drug development. He is a pharmacist by training and holds a PhD in Medicinal-/Computational Chemistry. Previously he worked at Probiodrug AG (now Vivoryon AG) for more than 10 years on several positions, before he was a group leader for medicinal and analytical chemistry at Fraunhofer IZI-MWT. He is one of the co-founder of the company as a spin-off from the institute.

Pierre Tangermann

CEO

Pierre holds the CEO position of PerioTrap Pharmaceuticals GmbH. Previously, he has served as business development manager at the Fraunhofer-Institute for Cell Therapy and Immunology in Leipzig and was later heading the business development and marketing department of its subsidiary in Potsdam. He graduated in Biochemistry (M.Sc.) at Leipzig University and the University of Queensland as well as in General Management (M.A.) at the University of Applied Sciences Leipzig.

Dr. Nadine Taudte

Senior Scientist

Our Senior Scientist Nadine holds a diploma in Biology and a PhD in Molecular Microbiology from MLU Halle/ Wittenberg with residences at the University of Arizona and Nebraska-Lincoln. After working several years in drug development for a BioTech Company and Fraunhofer in the field of target validation, Nadine now closes the gap to her microbiological roots supervising our pathogenic work and drug testing.

Team members Reihe 2

Anett Theisen

Clinical Manager

Anett is a highly skilled professional with a Diploma in Biology from the University of Bayreuth. Boasting 17 years of invaluable experience in the execution of clinical trials and the development of quality management systems, Anett has demonstrated a consistent commitment to excellence. Her expertise in Good Clinical Practice (GCP) and vendor auditing will seamlessly integrate these roles into the overarching quality management framework. Her proficiency ensures meticulous compliance and upholds the highest standards in the execution of clinical trials.

Grit Rehbein

Product Developer

Grit currently works in Project Management, Product Development, and Quality Management. With 20 years of comprehensive experience in Research and Development (R&D) and scientific management within the biomedical research sector, including a PhD and PostDoc at Uniklinik Halle, the medical faculty of MLU, she brings a seasoned perspective and proven expertise to her current roles at PerioTrap. In the last 8 years, Grit has developed products and ensured Quality Management in line with ISO 13485 standards. Her accomplishments include setting up small-series production and contributing to planning a fully automated production line for In Vitro Diagnostics (IVDs).

Advisory Board

Prof. Dr. Hans-Ulrich Demuth

Honorary Professor of Proteinbiotechnolgy, Department of Biotechnology, Anhalt University of Applied Science, Köthen, Germany

Prof. Dr. Sigrun Eick

School of Dental Medicine, University of Bern

Prof. Dr. Jan Potempa

Head of Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland and Distinguish University Scholar, Department of Oral Immunity and Infectious Diseases, University of Louisville School of Dentistry, Louisville, KY, USA.

Prof. Dr. Dr. h.c. Holger Jentsch

Clinic for Cariology, Endodontology and Periodontology, University Hospital of Leipzig.

Dr. Özlem Weiss

IBD Consulting & Co.

Prof. Dr. Karsten Mäder

Pharmaceutical Technology, Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle, Germany